ReWalk Robotics Reports Third Quarter 2015 Financial Results YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA

ReWalk Robotics Reports Third Quarter

2015 Financial Results

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, November 5, 2015

- ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") today announced its financial

results for the three- and nine-months ended September 30, 2015.

Highlights of and subsequent to the third quarter include:

"In the year since we received FDA

clearance, we have significantly transformed from a limited personal pay and rehabilitation directed business to focus on the substantially

larger market opportunity with reimbursement coverage for personal use devices. We are confident that our market building activities

will drive demand for ReWalk systems worldwide, and our efforts on the reimbursement front will continue to demonstrate progress.

During the third quarter, we increased reimbursement submissions to 99 pending claims, and received ten favorable coverage decisions.

We plan to advance our work to educate the market and insurers about the health and economic benefits of the ReWalk systems with

additional published data in the coming months," said Larry Jasinski, Chief Executive Officer.

"As we continue to make significant

progress executing our commercial and development strategies, we are encouraged by the market acceptance of the ReWalk Personal

6.0 unit, launched in July 2015. It is a major advance forward in exoskeleton technology, significantly enhancing the user experience.

As we execute our strategic plan, we believe we can drive increased sales and market penetration in order to continue to build

shareholder value for the long-term," Jasinski concluded.

Third Quarter 2015 Financial

Total revenue was $1.2 million for

the third quarter of 2015, compared with $1.5 million during the third quarter of 2014, and up sequentially from $610,000 in the

second quarter of 2015. In the third quarter of 2015, 23 ReWalk systems were placed compared with 27 ReWalk systems placed in the

Gross profit in the third quarter was

$87,000, compared to a gross profit of $331,000 for the third quarter of 2014 reflecting lower sales volumes and additional production

Total operating expenses in the third

quarter of 2015 were $6.4 million, versus $8.1 million in the third quarter of 2014. Operating expenses in the third quarter of

2015 reflect increased investment in sales and market development activities and the additional costs of being a public company.

Operating expenses in the third quarter of 2014 were impacted by a non-cash share based compensation charge of $4.1 million related

Net loss was $6.4 million for the

third quarter of 2015 versus a net loss of $6.4 million for the same period last year. Non-GAAP net loss for the third quarter

was $5.9 million compared with non-GAAP net loss of $3.5 million in the prior year quarter.

A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release.

Nine Months Ended September 30,

2015 Financial Results

Total revenues were $2.4 million for

the nine months ended September 30, 2015, compared with $2.5 million during the prior year period. In the 2015 nine-month

period, 48 ReWalk systems were placed compared to 43 ReWalk systems placed during the same period in 2014.

Gross profit was $180,000 for the nine

months ended September 30, 2015, compared to a gross loss of $92,000 for the nine months ended September 30, 2014.

Total operating expenses were $17.8

million for the nine months ended September 30, 2015 versus $14.6 million in the prior year period, reflecting investment in reimbursement

and market development activities, and the cost of being a publicly-traded company.

Operating loss for the nine months

ended September 30, 2015, was $17.7 million compared with $14.6 million during the prior year period.

Net loss for the nine months ended

September 30, 2015 was $17.9 million compared with a net loss of $16.2 million during the nine months ended September 30, 2014.

Non-GAAP net loss was $16.2 million for the nine months ended September 30, 2015, compared with non-GAAP net loss of $10.1 million

for the same period last year.

As of September 30, 2015, ReWalk had

$25.1 million in cash and no debt.

ReWalk management will host its third

quarter conference call as follows:

A telephone replay will be available

shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode

for the replay is 64363618.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures

and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk's mission is to fundamentally

change the health and life experiences of individuals with spinal cord injury. Founded in 2001, ReWalk has headquarters in the

U.S., Israel and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.

Forward Looking Statements

This press release contains forward-looking

information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking

statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s),"

"will," "may," "intends," "anticipate(s)," "look forward," "upcoming,"

"plan," "enables," "potentially," "entitles," and similar expressions are intended

to identify forward-looking statements. All such statements are subject to certain risks and uncertainties, many of which are difficult

to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed

in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are

not limited to the following: the market for medical exoskeletons is new and unproven, and important assumptions about the potential

market for ReWalk's products may be inaccurate; the Company has a limited operating history upon which you can evaluate its

business plan and prospects; if ReWalk is unable to expand its sales, marketing and training infrastructure, it may fail to increase

its sales; the health benefits of ReWalk have not been substantiated by long-term clinical data, which could limit sales; the Company

may fail to secure or retain adequate coverage or reimbursement for ReWalk by third-party payers; the Company depends on a single

third-party to manufacture ReWalk and a limited number of third-party suppliers for certain components of ReWalk; the Company's

future growth and operating results will depend on its ability to develop and commercialize new products and penetrate new markets;

the Company operates in a competitive industry that is subject to rapid technological change, and we expect competition to increase;

and the Company is subject to extensive governmental regulations relating to the manufacturing, labeling and marketing of its products. These

and other risk factors are set forth in the Company's final Annual Report on Form 20-F for the year-ended December 31, 2014

filed with the Securities and Exchange Commission on February 27, 2015, and the Company's other reports filed from time to

time with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking

statements that speak only as of the date hereof. ReWalk does not undertake any obligation to revise and disseminate forward-looking

statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

ReWalk is a registered trademark

of ReWalk Robotics Ltd. in Israel.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are

prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of

non-GAAP accounting measures, including non-GAAP net loss is helpful to its investors. These measures, which the Company refers

to as non-GAAP financial measures, are not prepared in accordance with GAAP.

For the three- and nine-months ended September 30, 2015 and

2014, non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense and (ii) the

revaluation of warrants to purchase convertible preferred shares.

Because of varying available valuation methodologies, subjective

assumptions, and the variety of equity instruments that can impact a company's non-cash expenses, the Company believes that

providing non-GAAP financial measures that exclude share-based compensation expense and non-cash financial (income) expenses allow

for more meaningful comparisons between operating results from period to period. Each of the Company's non-GAAP financial

measures is an important tool for financial and operational decision-making and for evaluating our own operating results over different